NASDAQ:NEUP Neuphoria Therapeutics Q3 2025 Earnings Report $3.92 -0.01 (-0.13%) As of 02:35 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Neuphoria Therapeutics EPS ResultsActual EPS$6.55Consensus EPS -$0.47Beat/MissBeat by +$7.02One Year Ago EPSN/ANeuphoria Therapeutics Revenue ResultsActual Revenue$15.00 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANeuphoria Therapeutics Announcement DetailsQuarterQ3 2025Date5/20/2025TimeAfter Market ClosesConference Call DateTuesday, May 20, 2025Conference Call Time8:00AM ETUpcoming EarningsNeuphoria Therapeutics' Q4 2026 earnings is estimated for Wednesday, September 2, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Neuphoria Therapeutics Earnings HeadlinesThe M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—NRIM, NEUP, SAFT, and RMAXJuly 30, 2026 | globenewswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—PBCO, NEUP, SAFT, and PFLCJuly 28, 2026 | globenewswire.comNvidia's CEO says this small device is critical for AI growthA tiny glass device smaller than a fingertip could redefine AI hardware. Nvidia CEO Jensen Huang calls it essential for AI to scale, while Sequoia Capital labels it a holy grail. Stocks tied to this technology have already surged 133 percent, 217 percent, and 320 percent in recent months, according to Brownstone Research analyst Jason Bodner, who identified Nvidia at 4.50.August 4 at 1:00 AM | Brownstone Research (Ad)Wall Street Zen Upgrades Neuphoria Therapeutics (NASDAQ:NEUP) to HoldJuly 25, 2026 | americanbankingnews.comNEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its ShareholdersJuly 24, 2026 | businesswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP)July 24, 2026 | prnewswire.comSee More Neuphoria Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Neuphoria Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neuphoria Therapeutics and other key companies, straight to your email. Email Address About Neuphoria TherapeuticsNeuphoria Therapeutics (NASDAQ:NEUP), Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.View Neuphoria Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles The AI Chip Stock Making a Quiet Move Toward DominanceApple’s AI Strategy Looks Different—Will It Pay Off?Reddit’s U.S. User Decline Raises a Bigger Question After Its Earnings BeatWhy Walmart and Amazon Could Be the Market’s Most Complementary Mega-CapsMarriott’s Earnings Drop May Be Missing the Bigger Fee Growth StoryDodging Deutsche Telekom: T-Mobile's Strategic WinSpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control Upcoming Earnings DoorDash (8/5/2026)Walt Disney (8/5/2026)MercadoLibre (8/5/2026)Occidental Petroleum (8/5/2026)Phillips 66 (8/5/2026)Allstate (8/5/2026)Brookfield Asset Management (8/5/2026)MetLife (8/5/2026)Manulife Financial (8/5/2026)Block (8/5/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
